Sign Out
Pregnancy: There is no clinical experience involving pregnant women. In rats, caspofungin caused decreases in fetal body weights and an increase in the incidence of incomplete ossification of the skull and torso, at a maternally toxic dose of 5 mg/kg/day. In addition, at this same maternally toxic dose, there was an increase in the incidence of cervical rib in rats. Caspofungin has been shown to cross the placental barrier in animal studies.
CANCIDAS should not be used during pregnancy unless clearly necessary.
Nursing Mothers: It is not known whether this drug is excreted in human milk; therefore, women receiving CANCIDAS should not breast-feed.
